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Abstract
Rationale—The active component of cannabis, delta-9 tetrahydrocannabinol (THC), has a long
half-life and widespread neurocognitive effects. There are inconsistent reports of neurocognitive
deficits in adults and adolescents with cannabis use disorders (CUD), particularly after a period of
abstinence.
Objectives—To examine neurocognitive measures (IQ, academic achievement, attention,
memory, executive functions) in abstinent adolescents with CUD, while controlling for
demographic, psychopathology, and poly-substance confounders.
Methods—We investigated neurocognitive performance in three groups: adolescents with CUD
after successful first treatment and in full remission (n=33); controls with psychiatric disorders
without substance use disorder history (n=37); and healthy adolescents (n=43).
Results—Adolescents with psychiatric disorders, regardless of CUD status, performed
significantly worse than the healthy adolescents in academic achievement. No group differences
were seen in IQ, attention, memory, or executive functions. Lower academic achievement was
positively associated with younger age of CUD onset, regular cannabis use, and maximum daily
use. In the CUD group, lifetime nicotine use episodes were negatively associated with IQ. Lower
overall neurocognitive function was associated with younger age of onset of regular cannabis use
and relapse within the one year follow-up.
Conclusions—Verifiably abstinent adolescents with CUD history did not differ from the two
comparison groups, suggesting that previously reported neurocognitive deficits may be related to
other factors, including residual drug effects, pre-existing cognitive deficits, concurrent use of
other substances (e.g., nicotine), or psychopathology. Adolescents with CUD may not be
vulnerable to THC neuropsychological deficits once they achieve remission from all drugs for at
least 30 days.
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Introduction
Adolescent cannabis use has increased in recent years, with approximately 25% of eighth
grade students and nearly 40% of high school seniors reporting use (Johnston et al., 2012).
The active component of cannabis, 9-tetrahydrocannabinol, or THC, is the most frequently
used illicit drug (Substance Abuse and Mental Health Services Administration, 2010). THC
acts as an exogenous agonist for endogenous cannabinoid pre-synaptic receptors.
Endogenous cannabinoids play an important role in the control of the neural circuits and
structures (e.g., the prefrontal cortex and hippocampus) involved in attention, executive
function and memory. These brain structures and their circuits actively mature during
adolescence. Animal studies demonstrate that adolescent cannabis use can affect the brain
regions involved in these neurocognitive functions (Rubino et al., 2009) and may
permanently impair adolescent neurocognitive functions (Crews et al., 2007; Schweinsburg
et al., 2008a). Further, THC has a long half-life and is lipophilic. THC is distributed to
adipose tissue, liver, lung, spleen, and the brain’s myelin. THC is then slowly released back
into the blood and metabolized, which can last from 5 to 95 days in heavy regular users
(Musshoff & Madea, 2006). Thus, any toxic disruptions to these developing brain processes
during adolescence may occur weeks to months after cannabis consumption and lead to a
variety of neurocognitive difficulties in attention, memory, and executive functions.
Reports of neurocognitive deficits among individuals with cannabis use disorder (CUD)
have been inconsistent. Previous findings of cognitive deficits in adolescents and adults with
CUD had difficulty in separating residual effects of THC metabolites, the effects of alcohol
and other drugs, pre-existing cognitive deficits that are common to the co-morbid
psychopathology seen in adolescents with CUD, and/or pre-existing cognitive deficits that
make one vulnerable to addictions and are present prior to drug misuse. Studies of adult
cannabis users demonstrated deficits in verbal fluency, working memory, attention
regulation, visual-spatial abilities, immediate and delayed memory functions, and executive
functions (Ashton, 2001). However, in most studies the CUD subjects were abstinent for
hours (Block & Ghoneim, 1993; Kanayama et al., 2004; Solowij et al., 2002), weeks
(McHale & Hunt, 2008), and up to one month (Bolla et al., 2002; Lyons et al., 2004); so
residual effects of THC metabolites may have confounded the results. Some adult studies
have shown little or no difference in working memory and attention in cannabis users when
compared to controls (Jager et al., 2006), leading some investigators to suggest that there are
few long-term cognitive consequences of cannabis use (Gonzalez et al., 2002; Iversen, 2005;
Pope et al., 2001; Pope & Yurgelun-Todd, 2001). One study reported that current cannabis
use, particularly with increasing amounts, was related to declining IQ scores; however, no
decline was reported in former users (Fried et al., 2002). These investigators later showed
that cognitive deficits associated with the residual effects of THC were seen for up to 3-
months post abstinence in young adults (Fried et al., 2005). In a study of adults recruited
from the prospective longitudinal Dunedin Study, neuropsychological function was
examined at age 13 (prior to the onset of cannabis use) and age 38 (Meier, et al., 2012).
These investigators found that persistent cannabis use for over 20 years was associated with
a decline of global, as opposed to specific, neurocognitive functions, which persisted after
adjusting for education and a variety of alternative explanations (e.g., recent use, nicotine or
other drug dependence including alcohol, schizophrenia). Furthermore, their findings were
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associated with adolescent-onset cannabis use more than adult-onset use suggesting that the
adolescent brain may be more vulnerable to cannabis related neuro-toxicity (Meier, et al.,
2012). However, these authors did not obtain urine THC levels on their subjects so a direct
pharmacological or residual effect of THC on global neurocognitive functions could not be
determined.
Although the neurocognitive effects of adolescent CUD are understudied, these studies also
show deficits in psychomotor speed, verbal fluency, working memory, attention, visual-
spatial abilities, immediate and delayed memory functions, and executive functions, in
adolescents who were abstinent hours (Harvey et al., 2007; Lane et al., 2007), days (Fontes
et al., 2011; Grant et al., 2012), weeks (Hanson et al., 2010; Lisdahl & Price, 2012; Medina
et al., 2007), and up to one month (Millsaps et al., 1994); so residual effects of THC
metabolites may have also confounded the results.
Adolescent onset CUD commonly occurs with co-morbid DSM Axis I disorders including:
alcohol use disorder and nicotine dependence (Clark, 2004; Lynskey et al., 2003); disruptive
behavior disorders (Armstrong & Costello, 2002; Costello et al., 2003); and affective
disorders (Degenhardt et al., 2003; Dembo et al., 1988). Similar psychiatric co-morbidity is
common in adult CUD (Stinson et al., 2006). Individuals who use cannabis often use other
substances such as alcohol and nicotine which may affect their neurocognitive function.
Abstinent cannabis users who were also smokers, performed worse on tests of sustained
attention and working memory than controls (Jacobsen et al., 2004), and delayed recall of
verbal memory deteriorated significantly during nicotine withdrawal compared with controls
(Jacobsen et al., 2007). Some investigators have argued that psychiatric and other drug co-
morbidity may actually account for more of the variance than cannabis use itself in the rates
of addiction and drug recidivism in adolescents (Kaminer & Bukstein, 2008; Spear et al.,
1999). To date, most of the available adolescent cannabis studies (Fontes, et al., 2011;
Grant, et al., 2012; Hanson, et al., 2010; Harvey, et al., 2007; Medina, et al., 2007) have
controlled for the presence of mood, anxiety, and psychotic disorders but have not controlled
for the presence of disruptive disorders or trauma such as child protective services history,
all of which are commonly seen in adolescent substance use disorder (SUD)(Clark, 2004;
Clark et al., 1997). Many previous studies that controlled for co-morbidity did not control
for the residual effects of THC on brain function (Fontes, et al., 2011; Grant, et al., 2012;
Hanson, et al., 2010; Harvey, et al., 2007) or the presence of disruptive disorders (Lisdahl &
Price, 2012). Furthermore, studies that controlled for psychiatric co-morbidity were only
able to control for co-morbid heavy alcohol and nicotine use statistically (Medina, et al.,
2007). Also, most of the above studies did not control for prenatal exposure to drugs,
psychiatric disorders, residual effects of THC (e.g., verifiable abstinence for at least 30 days
with negative urine THC levels), or other substance use.
To address these limitations, we designed a study that controlled for these factors while
examining the neurocognitive effects of CUD in adolescents. We cross-sectionally
investigated neuropsychological performance in three groups of medically healthy
adolescents: Group 1: adolescents without any lifetime DSM-IV or DSM-5 axis I disorders
including substance use disorders and binge behaviors; Group 2: adolescents with
psychiatric disorders (psychopathology), but no lifetime DSM-IV or DSM-5 substance use
disorders including binge behaviors; and Group 3: adolescents with a primary diagnosis of
DSM-IV and DSM-5 CUD in full remission without current nicotine dependence and or
history of regular drinking. We hypothesized that abstinent adolescents with CUD would
perform worse on standardized neuropsychological measures of executive function and
memory than the two comparison groups. We further hypothesized that neurocognitive
performance would be related to cannabis consumption variables (e.g., age of onset of CUD,
Hooper et al. Page 3













duration of CUD). We also explored the relationship between neuropsychological measures
obtained at abstinence and relapse during the post-assessment one-year follow-up.
Method
Subjects
Thirty-three adolescents with current outpatient treatment for CUD who were in full
remission; 37 adolescent control outpatients with psychopathology commonly observed
among adolescents with CUD (Clark, 2004; Stinson, et al., 2006), but without any SUD
history (Group 2); and 33 healthy control adolescents participated (Table 1). The adolescent
controls with psychopathology and CUD groups were group-matched to have a similar
number of biological parents with lifetime SUD and were recruited through the same
outpatient university clinics, where core treatment is cognitive behavioral therapy with
family therapy. Healthy adolescents were recruited through local advertisements in the
surrounding community. The study was approved by the University Medical Center
Institutional Review Board. Adolescents provided written assent and legal guardians
provided written informed consent before participation.
Exclusion criteria for subjects were: (1) medical, neurological, or pervasive developmental
or psychotic disorders and daily prescribed medication use; (2) head injury, loss of
consciousness; (3) birth weight under 5 lbs. and/or postnatal compromise with neonatal
intensive care stay; (4) morbid obesity or growth failure; (5) IQ<80; (6) maternal tobacco
dependence, alcohol use greater than 4 drinks a month or use of illegal drugs during
pregnancy with adolescent participant (these data were collected upon interview with the
biological mother and subject birth/prenatal record review); (7) in all healthy controls,
lifetime history of DSM-IV or DSM-5 Axis I disorders confirmed by KSADS-PL interview;
(8) in healthy controls and controls with psychopathology, lifetime DSM-IV or DSM-5
SUD; (9) current SUD in the CUD group; and (10) all groups, positive urine or saliva
toxicology test for any substances including cotinine on the day of assessment.
Measures
Diagnoses were made using the Schedule for Affective Disorders and Schizophrenia for
School Aged Children Present and Lifetime Version (KSADS-PL) (Kaufman et al., 1997)
which was administered to all adolescents and their legal guardians as previously described
(De Bellis et al., 2009). Disorder onset, defined as the time at which diagnostic criteria were
first met, was determined for each disorder. If diagnostic disagreements were not resolved
with this method, consensus diagnoses were reached among a child psychiatrist (MDDB)
and child psychologist (SRH) using the Best Estimate Method (Clark, 1999; Kosten &
Rounsaville, 1992), where a date of onset, defined as the time at which diagnostic criteria
were first met, was determined for each disorder (Clark et al., 2001). If disorders occurred
within one month of each other, they were considered co-occurring. Substance use
information was gathered by directly interviewing adolescents. For each symptom, ages of
onset were estimated to the nearest month. Methods from the Lifetime History of Alcohol
Use Interview (Skinner, 1982) were incorporated into the KSADS-PL to collect
supplemental information on cannabis, alcohol and other abused substances, including
nicotine, and seven other drug classes (stimulants, sedatives/anxiolytics, cocaine, opioids,
hallucinogens, solvents/inhalants, and other). Additional information included average
quantity and frequency of use, age of onset of regular use (defined as use at least twice a
month for 2 months), maximum frequency and quantity of use, and age of maximum
frequency and quantity of use. The unit of cannabis use was a standard joint (Chung et al.,
2004).
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CUD patients were in Full Remission to meet criteria for the study. CUD patients also had to
be in remission of any cannabis use, alcohol use, nicotine use, or other SUD prior to study
enrollment. Most CUD patients were in DSM-IV-TR Early Full Remission (i.e., no cannabis
use for at least one month but less than 12 months) and only two patients were in Sustained
Full Remission (i.e., no cannabis use for 12 months or longer) but were maintained in
treatment secondary to cravings. However, all subjects met DSM-5 criteria for CUD in early
remission. Only one patient with CUD had a history of heavy drinking (defined as greater
than 200 lifetime episodes). The mean lifetime alcohol use episodes was significantly less in
the 18 CUD patients without alcohol abuse compared to the 15 CUD patients with alcohol
abuse (t1,32=2.0, p=.05). The mean lifetime number of drinks consumed was significantly
less in the 18 CUD patients without alcohol abuse compared to the 15 CUD patients with
alcohol abuse (t1,32=2.42, p=.02). The mean lifetime nicotine use episodes was significantly
less in the 16 CUD patients without nicotine dependence compared to the 17 CUD patients
with nicotine dependence (t1,32=3.65, p=.001). The mean lifetime number of cigarettes
consumed was less in the 16 CUD patients without nicotine dependence compared to the 17
CUD patients with nicotine dependence (t1,32=1.93, p=.06). Note the CUD patient’s primary
drug of choice and primary addiction was cannabis; they did not have significant history of
misuse of other illicit drugs, which was an exclusion for this study (Table 2).
One year after the assessment, CUD subjects and their guardians underwent a telephone
interview to determine CUD relapse.
No subjects were taking psychotropic or other daily medications at the time of the study.
Note that, as commonly seen in adolescent subjects with Axis I disorders, who may have
benefited from medications, these adolescents had chosen to refuse medications prior to
being informed of this study. No subjects were asked to stop prescribed medications to be in
this study. All adolescents received saliva and urine toxicology screens prior to
neurocognitive testing to confirm the absence of THC, alcohol, tobacco, or other drug use.
Any participants with a positive screen were excluded from this investigation and not
reported here.
Neurocognitive Outcomes—Intelligence (IQ) was determined using the Wechsler
Abbreviated Scale of Intelligence (WASI,Wechsler, 1997). For this study, we used two
subtests (Vocabulary and Matrix Reasoning) to generate an estimated Full Scale IQ.
Academic achievement was assessed using the reading and math subtests of Woodcock-
Johnson-III Tests of Academic Achievement (WJ-IIIWoodcock et al., 2001) to generate
overall scores for each academic domain.
For attention, the Conner’s Continuous Performance Test (CPT-II, Conners & MHS Staff,
2000) provided age-based standard scores for Errors of Omission, Variability, and Reaction
Time. The Errors of Commission variable was included as a measure of inhibitory control
under the domain of executive functions. Other measures of executive function included the
Delis-Kaplan Executive Function System (D-KEFS, Delis et al., 2001) subtests of Tower,
Color-Word Interference, and Trail-Making, Wisconsin Card Sorting Test (Heaton, 1981);
WJ-III Tests of Cognitive Abilities Auditory Working Memory Cluster (Woodcock, et al.,
2001); and the age-appropriate version of the California Verbal Learning Test (CVLT-C or
CVLT-II) (Delis et al., 1994, 2000) perseverations score. For memory, we used the age-
appropriate version of the CVLT, the Rey-Osterrieth Complex Figure Delay (Duley et al.,
1993), and the Wide Range Assessment of Memory and Learning (WRAML) (Sheslow &
Adams 1990) indices of verbal memory, verbal recognition, visual memory, and visual
recognition.
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Preliminary data analyses showed group differences on the sociodemographic variables,
child protective services history, and the presence of psychiatric disorders. ANOVA with
follow-up pairwise comparisons were used for continuous variables, or Chi Square for the
categorical variables. Since the CUD group differed from the controls with psychopathology
in ADHD Combined Type and Conduct Disorder, we controlled for these disorders. To
address the first hypothesis, we employed ANCOVA and four MANCOVAs, controlling for
any sociodemographic variables and the presence of ADHD Combined Type and Conduct
Disorder, to determine the presence of group differences across the three groups on IQ, the
academic achievement, attention, memory, and executive function domains, respectively.
Follow-up pair-wise comparisons were done using Tukey-Kramer HSD or Post-hoc
Analysis of Means of Proportion for categorical data. Effect sizes, using Partial Eta Square
(η2) were calculated for significant group differences (Small = .06–.12; Medium = .13–.16;
Large > .16)(Cohen, 1988). To address the second hypothesis, we conducted Spearman’s
Rho Correlations with only the CUD participants to examine the degree of the relationship
between targeted CUD-related and other substance consumption variables (e.g., age of onset
of CUD, CUD duration) and summary indices for IQ, achievement, and neurocognitive
functioning. For data reduction purposes, the standard scores for the academic variables and
neurocognitive measures, respectively, were averaged to generate a single achievement and
a single neurocognitive summary variable.
Results
Preliminary Analyses
The three groups did not differ in age, sex, height, weight, head circumference, caregiver IQ,
socioeconomic status, race/ethnicity, handedness, and parental family history of SUD.
Because our treatment center had a majority of male adolescents with CUD, there was a
nonsignificant trend (p < .09) for more males in the CUD group.
The Adolescent Controls with Comorbid Psychopathology (Mean 2.38±1.1) without
Substance Abuse and CUD (2.76 ±1.15) groups were similar on number of Axis I disorders
in past 12 months, presence of any mood and anxiety disorders, presence of oppositional
defiant disorder, and history of child protective services involvement (Supplemental Table
1). The CUD group was significantly greater than the Adolescent Controls with
Psychopathology without Substance Abuse in disruptive behavior psychopathology on
ADHD Combined Type and Conduct Disorder; as stated, these latter variables were used as
covariates in our group comparisons. It should be noted that the diagnosis of conduct
disorder in the CUD sample was directly related to cannabis use and co-occurred with their
initial cannabis abuse diagnosis. For example, these CUD subjects made conduct disorder
criteria because they lied, skipped school, were out past curfew or overnight to use cannabis.
Group Differences
Group comparison data and effect sizes are shown in Table 3. Specifically, after controlling
for ADHD Combined Type and Conduct Disorder, the three groups were not significantly
different on IQ, attention, memory, or executive functions. There were no group differences
in these cognitive domains when we ran the analyses with 1) only the 25 CUD patients who
had greater than 200 lifetime cannabis consumption episodes or controlling for lifetime
cannabis use or consumption variables; 2) controlling for alcohol abuse history, lifetime
drinking episodes, or lifetime number of drinks; or 3) controlling for nicotine dependence
history, lifetime smoking episodes, or lifetime number of cigarettes.
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Adolescents with psychiatric disorders, regardless of CUD status performed significantly
worse than controls in academic achievement, (F (16, 202) = 2.18, p < .007). Follow-up
univariate analyses revealed that Groups 2 and 3 preformed lower in reading (F (2, 108) =
4.96, p < .009), and the associated subtests of reading fluency and reading comprehension,
with small effect sizes (η2 = .06 to .098). For nearly all of the reading tasks, the two clinical
groups performed below the healthy control group. Follow-up univariate analyses revealed
that Groups 2 and 3 performed lower in the math domain (F (2, 108) = 5.62, p < .005), with
all math subtests showing the two clinical groups below the healthy control group. Effect
sizes were small (η2 = .063 to .097). There were no significant differences between the CUD
group in remission and Adolescent Controls with Psychopathology without SUD history
groups on any of the academic achievement comparisons.
CUD-Related Correlates of Intellectual, Achievement, and Neurocognitive Functions
The age of CUD onset (Spearman’s rho =45, p<.01), age of onset of regular use
(Spearman’s rho =47, p<.01), and age of maximum daily use (Spearman’s rho =40, p<.05)
were positively correlated with Academic Achievement. The younger the age of CUD onset
variables the lower the overall achievement score. Similarly, the age of onset of regular use
correlated positively, and to a moderate degree, the Neurocognitive summary variable
(Spearman’s rho =40, p<.05). There were also trends showing that the age of CUD onset
(Spearman’s rho =.33, p<.1) and number of joints used per week (Spearman’s rho =−.32,
p<.1) were negatively associated with the neurocognitive summary variable, and that the
longer the time since cannabis last use (Spearman’s rho =.29 p<.1), the higher the IQ. Note
there were no significant correlations with lifetime cannabis use or consumption variables
and IQ, achievement, or neurocognitive functions. In the CUD group, lifetime nicotine use
episodes were negatively associated with IQ (Spearman’s rho =−.38, p<.01) and there was a
trend that nicotine dependence history was negatively associated with IQ (Spearman’s rho =
−.31, p<.1). CUD patients with histories of alcohol abuse and their alcohol consumption
variables did not influence the results.
Of the 33 CUD subjects, 5 were lost to follow-up at the one-year telephone assessment;
while of the remaining 28, 20 (72%) relapsed while 8 remained drug-free. This rate is
similar to the high rates of relapse previously described in adolescents treated for SUD
(Williams et al., 2000). The Neurocognitive Summary score significantly correlated with
relapse (Spearman’s rho=−.39, p<.04) and the Achievement Summary suggested
(Spearman’s rho =−.35, p<.07) relapse during the one year follow-up, such that the lower
the neurocognitive score, the greater the risk of cannabis relapse. Youth IQ did not correlate
with relapse.
Discussion
This study examined neurocognitive deficits among verifiably abstinent adolescents with
primary CUD who were in remission and not currently using alcohol or nicotine. These
subjects were compared to healthy controls and to non-cannabis users with psychiatric
disorders commonly observed in CUD patients. The abstinent CUD Group did not differ
markedly from the two comparison groups, suggesting that previously reported
neurocognitive deficits may be related to other factors, including residual THC effects, pre-
existing cognitive deficits, concurrent use of other substances (e.g., nicotine), or psychiatric
symptoms.
Previous studies of adolescent cannabis users found decreased attention, memory, and
executive function (Harvey et al., 2007; Lane et al., 2007; Fontes et al., 2011; Grant et al.,
2012; Hanson et al., 2010; Lisdahl & Price, 2012; Medina et al., 2007; Millsaps et al., 1994).
In those studies, however, results may have been related to the residual effects of cannabis,
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or cannabis or nicotine withdrawal. Similarly, our findings were not consistent with the few
studies to date showing subtle impairment in memory and executive functions from cannabis
use in adolescents with CUD who were abstinent for at least 3 weeks (Medina, et al., 2007;
Schwartz et al., 1989). Our CUD subjects differed from those of Medina et al., 2007 in that
our CUD subjects reported less mean lifetime alcohol use episodes, less mean lifetime
cannabis use episodes, had no history of regular drinking, were abstinent for at least 30 days
from all substances, had no alcohol withdrawal symptoms, and were appropriately 1.5 years
younger than the subjects studied by Medina et al., 2007. These factors, particularly the
greater age of subjects in the Medina et al., 2007 study, may have contributed to the
differences in findings between our study and those of Medina et al., 2007.
Our data demonstrated that: 1) the younger the age of onset of CUD, regular cannabis use,
and maximum daily use, the lower the overall achievement score; 2) the younger the age of
regular cannabis use, the lower the neurocognitive summary variables; and suggested that 3)
the age of CUD onset and number of joints used per week were negatively associated with
the neurocognitive summary variable. This suggests that younger adolescents may be more
sensitive to cognitive dysfunction. However, given our lack of clear group differences, we
may speculate that the young adolescent brain may be able to recover once drug use stops.
It is interesting that we found that lifetime nicotine use episodes were negatively associated
with IQ. Nicotine and cannabis dependences are frequently co-morbid (Clark, 2004;
Lynskey, et al., 2003). In a large prospective study, which controlled for child IQ,
educational attainment, occupation, and lung function, smoking history was a significant
independent predictor of cognitive function at age 64 (Whalley et al., 2005). In adults,
nicotine dependence was negatively associated with prefrontal grey matter and anterior
cingulate volumes, brain structures that are important for intact cognitive function (Brody et
al., 2004). Thus, adolescent nicotine dependence may be an underexplored co-morbid
addiction that contributes to the cognitive dysfunction previously reported in adolescent
cannabis users.
Our neurocognitive findings do align with the few available negative studies that have
addressed this issue in abstinent adolescents and adults (Fried, et al., 2005; Fried, et al.,
2002; Gonzalez, et al., 2002; Iversen, 2005; Pope, et al., 2001). Specifically, Fried and
colleagues (Fried, et al., 2005; Fried, et al., 2002) reported that problems with learning,
working memory, processing speed and memory abilities resolved once the adolescents with
CUD discontinued use of cannabis, including heavy cannabis users (i.e., >5 joints per week).
Interestingly, the mean abstinent time frame noted in our study (i.e., approximately three
months) and average use of 17 joints per week were consistent with the findings of Fried
and colleagues. This study strengthens this assertion in the debate by including additional
methodological controls for the effects of residual THC and psychiatric and substance use
co-morbidity.
The current study did not show the abstinent CUD Group to be significantly lower in IQ,
attention, memory, or executive functions than either control group. However, in the area of
academic achievement, the CUD group performed significantly lower than the Healthy
Adolescent Group, but they were not lower than the adolescent controls with comorbid
psychopathology without substance use disorder history. This was true for both reading and
math skills. These findings continue to support the idea that once concomitant psychiatric
disorders and other confounding factors are addressed, no unique academic effects are
observed in the CUD Group. Lower academic achievement is a consistent finding in
adolescents with non-psychotic psychiatric disorders (Nelson et al., 2004). However, our
finding does raise the question of academic need in this sample, even if these needs may be
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related more to lack of school attendance, academic self-esteem/involvement, and acute
effects of cannabis misuse during school attendance on the developing adolescent brain.
We found no unique differences associated with adolescent CUD in remission. However,
our correlational findings suggest that the younger the age of CUD onset and of maximum
daily use, the poorer the academic achievement score; and that the younger the age of onset
of regular cannabis use, the poorer the academic achievement and neurocognitive summary
scores, suggesting that adolescents may be more vulnerable to the brain effects of THC.
Thus, one may speculate that these findings imply that the adolescent brain may be more
vulnerable to the effects of THC but able to recover once the drug use stops. Our finding
that a younger age of CUD onset and more joints used per week was negatively associated
with the neurocognitive summary variable supports this idea. It is possible that the
adolescent brain may be able to recover from cannabis effects once a user becomes
abstinent. Our finding that the longer the time since cannabis last use, the higher the IQ also
supports this idea. Our correlational findings support previous data which suggest persistent
cannabis use is indicative of global impairment in neurocognitive abilities, with adolescent
use increasing the chances for long-term impairment (Meier et al., 2012). Given that the
Neurocognitive Summary score significantly correlated with relapse and the Achievement
Summary suggested relapse after clinic discharge and during the one year follow-up (such
that the lower the scores the greater the risk of cannabis relapse), our study may also support
that idea that cognitive deficits were present prior to drug misuse. Rigorously designed
longitudinal studies are needed to test these alternative hypotheses.
It is possible that standard neurocognitive tests are not sensitive enough to uncover unique
differences between adolescents with CUD and adolescents without any SUD but who suffer
from psychiatric disorders. Indeed, in a subsample of the males from this study, we found
that the CUD group differed from the controls with psychopathology and the healthy
controls on fMRI blood oxygen level dependent (BOLD) signal measures of decision-
making and reward evaluation, which correlated with relapse (De Bellis et al., 2013). Others
have also found significant BOLD differences in imaging studies between abstinent
adolescents with CUD and healthy controls in inhibitory processes (Tapert et al., 2007),
verbal working memory (Jacobsen, et al., 2007), and spatial working memory tasks (Padula
et al., 2007; Schweinsburg et al., 2008b).
Our study had several strengths. Our design insured that our results were not due to
sociodemographic factors, prenatal exposure of substances, prenatal factors, outpatient clinic
status, comorbid psychopathology, child maltreatment and trauma histories, greater familial
risk in the CUD group, or other polysubstance use. Our study also has several limitations as
our data were cross-sectional and had limited sample size. Given the small to moderate
effect sizes seen between groups, we may not have had enough power to detect differences
between the controls with psychopathology and the CUD group in remission; however, the
means of most neurocognitive measures were similar between these two groups.
In summary, this is a well-controlled investigation examining the neurocognitive functions
of abstinent adolescents with CUD. Few studies have examined this population with specific
inclusion of key comparison samples and potential influential covariates. While adolescence
is a sensitive period for ongoing development of the prefrontal cortex and hippocampus, and
a vulnerable time for disruption of such functions as attention, memory, and executive
capabilities, the adolescent brain may not be as vulnerable as previously believed to poor
performance on standard neuropsychological assessments from the effects of cannabis once
a user becomes abstinent from all drugs for at least 30 days. Previous findings of cognitive
deficits in adolescents with CUD may be related to other factors, such as residual effects of
THC metabolites, pre-existing cognitive deficits that were also common to co-morbid
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psychopathology, or pre-existing cognitive deficits that may have been present prior to drug
misuse. Given that our subjects’ Neurocognitive Summary scores significantly correlated
with relapse during the one year follow-up, our study suggests that subtle cognitive deficits
may have been present prior to drug misuse. Additional more sensitive measures such as
neuroimaging studies show further promise in the examination of the causes and
consequences of cannabis consumption on neurocognitive functions in the adolescent brain.
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Refer to Web version on PubMed Central for supplementary material.
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Table 2
Substance Use Characteristics of the Adolescent CUD group
Mean±SD Range
Number with History of DSM-IV-TR Cannabis Abuse Only 13
Number with History of DSM-IV-TR Cannabis Dependence 20
Number with History of DSM-IV-TR Cannabis Dependence with prior
Cannabis Abuse 18
Number with History of DSM-5 Cannabis Use Disorder (no/yes) 0/33
Number of CUD subjects with heavy use (defined as greater than 200
lifetime cannabis consumption episodes) 25 of 33
Age of CUD onset (years) 14.5±1.42 11–16.8
Age of CUD offset (years) 16.05±1.14 12.75–17.67
Time between the last cannabis use and testing (days) 110.7±110.0 30–480
Number of joints used per week during regular use 18.1±26.4 1–112
Age (years) of onset of regular cannabis use 14.19±1.53 10–16.4
Maximum Daily Cannabis Use (joints) 13.2 ±18.6 1–84
Age of Maximum Daily Cannabis Use 15.26±1.11 12–17
Lifetime Cannabis use episodes (days) 341.7±224.2 78–846
Lifetime cannabis consumption (number of joints) 2029±4339.1 39–24084
Number with History of Nicotine Dependence (no/yes) 16/17
Lifetime nicotine use episodes (days) 440.9±754.9 1–2670
Lifetime number of cigarettes 1907.3±5741.8 1–30600
The mean lifetime nicotine use episodes and range (days) in the 16 CUD
patients without nicotine dependence history. 28.7 ± 42.5 1–144
The mean lifetime number and range of cigarettes consumed in the 16
CUD patients without nicotine dependence. 31.9 ± 42.4 1–144
The mean lifetime nicotine use episodes and range (days) in the 17 CUD
patients with nicotine dependence history. 853.1 ±901.9 60–2670
The mean lifetime number and range of cigarettes consumed in the 17
CUD patients with nicotine dependence. 3782.6 ± 7786.6 240–30600
Number with History of Alcohol Abuse without regular drinking
(defined as alcohol use of at least 2 drinks a month for at least 2 months)
(no/yes).
18/15
Lifetime drinking episodes and range (days) in the CUD group 52.7±105.6 0–576
Lifetime number of drinks and range in the CUD group 272.8±508.5 0–2304
The mean and range of lifetime alcohol use episodes (days) in the 18
CUD patients without alcohol abuse. 20.8 ± 41.0 0–168
The mean lifetime number and range of drinks consumed in the 18 CUD
patients without alcohol abuse 90.3 ± 202.3 0–840
The mean and range of lifetime alcohol use episodes in the 15 CUD
patients with alcohol abuse. 91.0 ±143.5 10–576
The mean lifetime number and range of drinks consumed in the 15 CUD
patients with alcohol abuse 491.8 ± 668.6 20–2304
Abbreviations: CUD, adolescents with cannabis use disorder in full early remission;
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